⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IOVA News
Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
globenewswire.com
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
IOVA
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
globenewswire.com
IOVA
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
globenewswire.com
IOVA
Melanoma Diagnostics and Therapeutics Research Report 2026 - Global Market Trends, Competitive Analysis, Opportunities, and Forecasts, 2021-2025 & 2026-2031
globenewswire.com
MRK
IOVA
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica
globenewswire.com
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
IOVA
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
globenewswire.com
IOVA
NUTX
LNTH
MOH
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
IOVA
Humanetics Corporation Appoints Timothy E. Morris as Chief Operating Officer
businesswire.com
IOVA